Loading

logo

Journal of Clinical and Experimental Reproductive Medicine

ISSN: 3067-7904

Review Article Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.46439/reproductivemed.1.004

A scoping review of outcome measures in ovarian cancer clinical trials

Inga Wang1,*, Mohammad H Rahman2, Stephen Hou3, Hui-Wen Lin4
  • 1School of Rehabilitation Sciences & Technology, University of Wisconsin- Milwaukee, Milwaukee, WI, USA
  • 2Department of Biomedical Engineering / Mechanical Engineering, University of Wisconsin-Milwaukee, Milwaukee, WI, USA
  • 3School of Biomedical Sciences & Health Care Administration, University of Wisconsin-Milwaukee, Milwaukee, WI, USA
  • 4Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan
+ Affiliations - Affiliations

Corresponding Author

Inga Wang, wang52@uwm.edu

Received Date: July 27, 2024

Accepted Date: September 13, 2024

Citation:

Wang I, Rahman MH, Hou S, Lin HW. A scoping review of outcome measures in ovarian cancer clinical trials. J Clin Exp Reprod Med. 2024;1(1):26-39.


Copyright: © 2024 Wang I, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objective: The incorporation of patient-reported outcomes (PROs) is essential for assessing whether a cancer treatment enhances overall patient well-being, beyond merely extending survival. This scoping review aimed to identify and analyze the use of PROs in ovarian cancer clinical trials.

Methods: A comprehensive search was conducted in three databases (PubMed, CINAHL, and PsycINFO) to identify randomized controlled trials (RCTs) on ovarian cancer interventions published in peer-reviewed journals. Key study characteristics, including study design, participant demographics, and assessed outcomes, were extracted.

Results: Thirty-six studies were included in the review. The majority reported progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) as primary and secondary outcomes. Nineteen studies incorporated PROs as outcome measures. The most frequently utilized PRO instruments were the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30) and the EORTC Quality of Life Questionnaire Ovarian Cancer Module (EORTC QLQ-OV28). Other PROs included the EuroQol-5Dimensions (EQ-5D), Functional Assessment of Cancer Therapy–Epidermal Growth Factor Receptor Inhibitors?18 (FACT?EGFRI?18), Functional Assessment of Cancer Therapy–Ovarian (FACT?O), and NCCN-FACT Ovarian Symptom Index-18 (FACT NFOSI-18). This review summarized the PROs used as assessment endpoints in these trials.

Conclusion: This review highlights the significant yet underutilized role of PROs in ovarian cancer clinical trials and underscores the need for ovarian cancer-specific PROs to better assess treatment impact on patient quality of life.

Keywords

Ovarian cancer, Ovarian neoplasms, Patient-reported outcome measures, Quality of life, Treatment outcome

Recommended Articles

Neodymium:YAG laser posterior capsulotomy in the lateral decubitus position

Here we report a novel method of performing a Neodyminium:YAG (Nd:YAG) laser posterior capsulotomy in an adult patient, unable to tolerate the procedure awake with topical anaesthesia in the outpatient clinic setting. The procedure was performed by altering the chin rest and arms of the Nd:YAG laser machine so that the procedure could be undertaken in an anaesthetized patient in the operating theatre, in the lateral decubitus position, with the laser machine upright in its normal position.

Presbyopia correcting IOLs and the ocular surface disease… The good, the bad and the ugly

The last two decades were especially fruitful for the refractive surgeons and for the industry who have been showing tremendous development in both understanding and meeting patients’ desire for spectacle independence. Ever since the first trials from Dr. Kenneth Hoffer with his early 1980’s effort in producing a multifocal IOL to the latest achievements from different companies in putting trifocals and EDOF optics to the market.

How many mutations does it take to make a uveal melanoma?

Uveal melanoma (UM) is a rare cancer that affects the choroid and, less frequently, the ciliary body or the iris (for recent reviews see [1-3]). Despite a profound knowledge of the oncogenic mechanisms behind UM tumorigenesis and despite an accurate cytogenetic and molecular prognosis, only limited advances have been made in UM therapy.

MSICS is a Simple Solution for a Big Problem

Manual small-incision cataract surgery (MSICS) is a sutureless cataract surgery that has multiple advantages over traditional phacoemulsification and extracapsular cataract extraction (ECCE) procedures. SICS became the procedure of choice for international ophthalmology, where the microscopes and operating room can be more challenging, in addition to the more advanced pathology often seen.

Surgical smoke and SARS-CoV-2 transmission

The protection of health care workers from nosocomial infection is a paramount consideration in the current pandemic involving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Not only is prevention of viral transmission the most effective means to lessen the public health impact of coronavirus disease 2019 (COVID-19), but also both quarantine and illness – that disproportionately affect health care workers – have devastating effects on the ability of hospitals to adequately care for increased patient loads.

Full Text
Cite
Download PDF
Author Information X